BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback